MedTrace Logo

PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon

NCT03808142 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2021-08-25

No results posted yet for this study

Summary

In this study researchers wanted to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with Betaferon using the myBETAapp which includes the elements to what extent

* taking medication matched the presciber´s recommendation (adherence, compliance),
* treatment for the prescribed duration (persistence) was continued and
* injections were missed. Among MS patients treated with Betaferon using the myBETAapp the study also collected information on the health-related quality of life, treatment satisfaction and satisfaction with treatment support.

Conditions

Interventions

OTHER

myBETAapp

Patients choosing to use the myBETAapp were required to insert the Mixject number from their prescribed Betaferon box, which serves as an opening key for the app. Obtaining a new Betaferon box and obtaining a new Mixject number was not interfere with the process of continuously allocating data to a single patient; each patient had a unique personal identifier in the database. All data recorded in the myBETAapp including demographic and injection-related data were stored in the database once the mobile device was connected to the internet.

OTHER

PEAK

Peak is an application that aims at helping its users to challenge their brains and keep them sharp.

DRUG

Betaferon, BAY86-5046

Injection

DEVICE

BETACONNECT

BETACONNECT automatically records and stores injection-related details including injection time, speed, and depth upon every injection.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-20
Primary Completion
2020-04-20
Completion
2020-09-02

Countries

  • Germany

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03808142 on ClinicalTrials.gov